VHL and neoplasm: Remarkably, the in vivo tumor suppressor role of PBRM1 in ccRCC was confirmed and reported in 2017 by three independent laboratories using three different genetically engineered mouse models where combined losses of VHL and PBRM1 lead to multifocal ccRCC in mouse kidney, whereas individual losses did not [42, 54–55].